X4 Pharmaceuticals Inc (XFOR) Stock Price, Quote & News

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 529 8300

Website: www.x4pharma.com

Address:

61 North Beacon Street, 4th Floor, Boston, United States

DogCatcher123 Oct. 4 at 12:54 AM

$XFOR I’ve lost count of the number of shares outstanding for calculating fully diluted earnings per share purposes. Can anybody help?

1 · Reply

TwongStocks Oct. 3 at 9:42 PM

$XFOR Coastlands Capital, the lead investor from the August private placement, finally filed their 13G. https://www.sec.gov/Archives/edgar/data/1501697/000110465925096741/xslSCHEDULE_13G_X01/primary_doc.xml Reporting ownership of 2,491,638 pre-funded warrants, for 9.99% beneficial ownership "The calculation of the beneficial ownership of the Reporting Persons is based on (i) 22,449,689 shares of Common Stock issued and outstanding as of August 13, 2025, as reported by the Issuer in its Registration Statement on Form S-3 filed with the Securities and Exchange Commission on September 10, 2025, and (ii) 2,491,638 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%."

0 · Reply

Vikingsstrade Oct. 3 at 7:45 PM

$JBIO $XFOR $STSS $STKH Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!

0 · Reply

MoonCowBoy Oct. 3 at 1:01 AM

$JBIO $FOXO $XFOR $STSS ;

0 · Reply

MexaTraders Oct. 2 at 9:12 PM

What's happening on ticker ASTC right now?! Are they pumping ASTC for 300% next? Looks like its breaking out! Shorts overextended - Looks like its about to HALT UP and Squeeze any time! Some will buy it now some will chase it later - dont miss ASTC $IBRX $GLD $CIFR $AKBA $XFOR bio

1 · Reply

1Spartantrade1 Oct. 2 at 6:45 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $FOXO $XFOR $STSS $STKH 🔥

0 · Reply

Pope25 Oct. 1 at 8:45 PM

$XFOR no more $1.50. $5 now.

0 · Reply

ezg43 Oct. 1 at 8:29 PM

$SGMO $TNYA $XFOR $CAN $OPEN hmmmm what is next?

1 · Reply

sokrodney Oct. 1 at 8:25 PM

$XFOR this looks pretty good! I over looked this.... ima watch this..

0 · Reply

SpartansTrading Oct. 1 at 4:08 PM

$OPTHF last biotech Thesis $XFOR went .9-. 3.5

0 · Reply

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Aug 15, 2025, 4:05 PM EDT - 7 weeks ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 7:00 AM EDT - 7 weeks ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 12, 2025, 7:00 AM EDT - 7 weeks ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Jun 16, 2025, 8:00 AM EDT - 3 months ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 10, 2025, 8:00 AM EDT - 4 months ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

May 14, 2025, 4:12 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 1, 2025, 12:44 PM EDT - 5 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:01 AM EDT - 5 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 28, 2025, 7:16 AM EDT - 5 months ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

Apr 24, 2025, 8:03 AM EDT - 5 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:00 AM EDT - 5 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 23, 2025, 4:05 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 3:02 PM EDT - 6 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 6:01 AM EDT - 6 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 8:00 AM EDT - 7 months ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Feb 19, 2025, 7:35 AM EST - 8 months ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 6, 2025, 7:35 AM EST - 8 months ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Jan 24, 2025, 7:36 AM EST - 9 months ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 13, 2025, 7:35 AM EST - 9 months ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Nov 14, 2024, 8:00 AM EST - 11 months ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 13, 2024, 9:31 PM EST - 11 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:07 AM EST - 11 months ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:01 AM EST - 11 months ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 10, 2024, 9:30 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

May 29, 2024, 4:30 PM EDT - 1 year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 13, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 9, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 7, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 29, 2024, 5:02 PM EDT - 1 year ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 6:37 AM EDT - 1 year ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 1, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Mar 21, 2024, 11:35 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Dec 13, 2023, 11:43 PM EST - 1 year ago

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

Dec 9, 2023, 12:00 PM EST - 1 year ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Nov 10, 2023, 8:00 AM EST - 2 years ago

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

Nov 9, 2023, 12:37 PM EST - 2 years ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 6:01 AM EST - 2 years ago

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Nov 2, 2023, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

DogCatcher123 Oct. 4 at 12:54 AM

$XFOR I’ve lost count of the number of shares outstanding for calculating fully diluted earnings per share purposes. Can anybody help?

1 · Reply

TwongStocks Oct. 3 at 9:42 PM

0 · Reply

Vikingsstrade Oct. 3 at 7:45 PM

0 · Reply

MoonCowBoy Oct. 3 at 1:01 AM

$JBIO $FOXO $XFOR $STSS ;

0 · Reply

MexaTraders Oct. 2 at 9:12 PM

1 · Reply

1Spartantrade1 Oct. 2 at 6:45 PM

0 · Reply

Pope25 Oct. 1 at 8:45 PM

$XFOR no more $1.50. $5 now.

0 · Reply

ezg43 Oct. 1 at 8:29 PM

$SGMO $TNYA $XFOR $CAN $OPEN hmmmm what is next?

1 · Reply

sokrodney Oct. 1 at 8:25 PM

$XFOR this looks pretty good! I over looked this.... ima watch this..

0 · Reply

SpartansTrading Oct. 1 at 4:08 PM

$OPTHF last biotech Thesis $XFOR went .9-. 3.5

0 · Reply

BioRich Sep. 30 at 3:48 AM

$ALT Looks like Mr. "Transformative Year" got another "Transformative Year" guy as his CMO. Wait, didn't this new "Transformative Year" guy just get displaced when his company cut 50% of their work force? Hmmmm, seems about right. Enjoy! $XBI $XFOR

2 · Reply

BioRich Sep. 30 at 3:38 AM

$ALT Legit question for those heavily focused on ALT's science...How similar/interchangeable would the Chief Medical Officer's role at $XFOR be translated into Pemvi? On the surface, it seems like an awkward fit, but I don't have the technical background to answer so hoping someone could help (me and the Board). Cheers! @Cryptobearcat @Denzo2 @Wolly99 @Space_Dust @BTECHNIV aka @VINCE_CARTER

0 · Reply

BioRich Sep. 29 at 2:16 PM

$ALT How many more "Buddy" hires is $ALT going to make. Yet another hire to help an out of work buddy. When will y'all realize what's happening here? They are blatantly taking your money, and you defend them. There's really no hope for ALTers. ADS is a serious condition that currently has no treatment other than selling. Imagine how relieved you'd be if you sold this Gargage on June 25th before the tanking that I warned about? Sad. $XBI $XFOR

0 · Reply

BioRich Sep. 29 at 12:38 PM

$ALT Yaaaaaaasssss! Adding the guy from $XFOR as CMO. I implore each of you to look at $XFOR and their shenanigans. Perfect fit for $ALT. Dr. Harris is probably rolling over in his...

0 · Reply

Kevin73ca Sep. 29 at 12:19 PM

$XFOR bought on 18 Aug 2025 100 k average at 2.55 Still holding for double the money in coming days

0 · Reply

LegendaryCharts Sep. 28 at 6:24 PM

$PAVS Super Tiny float making a move north! Might be tomorrow pre-market runner. Bullish momentum! $XFOR swinging it $UPXI due for that big run soon $QMMM Recent rallies

0 · Reply

Duskfall Sep. 28 at 10:56 AM

$XFOR Solid company.. Swing thing📈✅

0 · Reply

MrWaikoloa Sep. 24 at 4:57 PM

$XFOR Buckle up. Feels like we’re setting up for a run like we had in the late summer.🤞

0 · Reply

GinoGino Sep. 24 at 1:09 AM

$XFOR This board is very quiet! Options for this stock don't seem to be standard contracts. Call options show: call x4 pharma = 3 xfor + cash. Any ideas what this means here?

1 · Reply

GinoGino Sep. 23 at 2:14 PM

$XFOR Looad up on Jan/2026 calls, very cheap, 5 cents! The potential here is enormous and so are the risks!

1 · Reply

MGeronimo Sep. 23 at 1:17 PM

$XFOR adding the dip at 3.36

0 · Reply

Pope25 Sep. 22 at 7:52 PM

$XFOR gonna reject $3.40 again?

0 · Reply

Market Cap	39.70M
Revenue (ttm)	2.56M
Net Income (ttm)	-37.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,462.89%
Debt to Equity Ratio	19.10

Volume	212,100
Avg Vol	4,664,780
Day's Range	N/A - N/A
Shares Out	11.41M
Stochastic %K	51%
Beta	0.54
Analysts	Strong Sell
Price Target	$8.70